BioPharma Resources

Drug Trial Radar · NCT07213817

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

114

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Oct 30, 2028

Study completion Oct 30, 2028

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phases: * Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose). * Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance). Study Periods: Screening: Up to 28 days before first IPN60300 injection to determine eligibility. Treatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor. Participants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • IPN60300Biological

    IPN60300 will be administered at assigned dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Percentage of participants with dose limiting toxicity (DLT)Time frame: within 21 days following study drug administration.
  2. Phase Ia and Ib: Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TE SAEs).Time frame: From the first IPN60300 administration until 30 days after the last dose
  3. Phase Ib: Objective response rate (ORR)Time frame: At end of study (up to approximately 3 years )

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center-Yale University

    New Haven, Connecticut · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau

    Saint-Herblain, France · Recruiting

  • Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy)

    Villejuif, France · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Not yet recruiting

  • NEXT Quiron-Barcelona

    Barcelona, Spain · Active not recruiting

  • START Madrid CIOCC Hospital Universitario HM Sanchinarro

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.